<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Risedronate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Risedronate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Risedronate: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11026" href="/d/html/11026.html" rel="external">see "Risedronate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F218582"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Actonel;</li>
<li>Atelvia</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868162"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AA-RISEDRONATE DR;</li>
<li>Actonel;</li>
<li>Actonel DR;</li>
<li>APO-Risedronate;</li>
<li>Auro-Risedronate;</li>
<li>DOM-Risedronate [DSC];</li>
<li>JAMP-Risedronate [DSC];</li>
<li>PMS-Risedronate;</li>
<li>RIVA-Risedronate;</li>
<li>SANDOZ Risedronate;</li>
<li>TEVA-Risedronate</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F218606"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Bisphosphonate Derivative</li></ul></div>
<div class="block doa drugH1Div" id="F218586"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Avoid use in patients with swallowing difficulties, esophageal motility disorders, or the inability to stand or sit upright for ≥30 minutes. In patients treated for osteoporosis, correct hypocalcemia and vitamin D deficiency (eg, to a 25-hydroxyvitamin D level ≥20 ng/mL [≥50 nmol/L]) prior to initiating therapy and ensure adequate calcium and vitamin D intake during therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30907953','lexi-content-ref-34448749','lexi-content-ref-Rosen.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30907953','lexi-content-ref-34448749','lexi-content-ref-Rosen.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="42d9f687-8a9c-4d6e-86a3-00829eb78170">Osteoporosis, fracture risk reduction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoporosis, fracture risk reduction: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Prior to use, evaluate and treat any potential causes of secondary osteoporosis (eg, severe vitamin D deficiency) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25182228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25182228'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Males and postmenopausal females:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients with high fracture risk, including those with a history of fragility fracture, </i>
<b>
<i>or</i></b>
<i> males ≥50 years of age and postmenopausal females with a T-score of −2.5 or lower or a T-score between −1 and −2.5 at high fracture risk according to a risk assessment </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Finkelstein.1','lexi-content-ref-25182228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Finkelstein.1','lexi-content-ref-25182228'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Treatment:</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Immediate-release tablet:</i>
<b>Oral:</b> 5 mg once daily <b>or</b> 35 mg once weekly <b>or</b> 150 mg once monthly.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Delayed-release tablet:</i>
<b>Oral: </b>35 mg once weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients without high fracture risk, including those with a T-score between −1 and −2.5 and who are </i>
<b>
<i>not</i></b>
<i> at high fracture risk according to a risk assessment, but who desire pharmacologic therapy to prevent bone loss or fracture</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254','lexi-content-ref-25182228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254','lexi-content-ref-25182228'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Prevention:</b> Immediate-release tablet: <b>Oral:</b> 5 mg once daily <b>or</b> 35 mg once weekly <b>or</b> 150 mg once monthly.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Duration of therapy:</b> The optimal duration of therapy has not been established. Consider discontinuing after 5 years if bone mineral density (BMD) is stable, there have been no previous fragility fractures, and short-term fracture risk is low. If fracture risk remains high (eg, fragility fracture before or during therapy), consider extending therapy for up to 10 years or switching to alternative therapy. If discontinued, the decision to resume therapy is based on multiple factors, including decline in BMD and risk factors for fracture (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26350171','lexi-content-ref-30907953','lexi-content-ref-20173017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26350171','lexi-content-ref-30907953','lexi-content-ref-20173017'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Glucocorticoid induced: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For use in males ≥50 years of age and postmenopausal females with low BMD (T-scores between −1 and −2.5 in either group) and expected to receive systemic glucocorticoid therapy for at least 3 months at a prednisone dose of ≥7.5 mg/day (or its equivalent) <b>or</b> in any patient whose baseline risk of fracture is high and is receiving a glucocorticoid at any dose or duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28585373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28585373'])">Ref</a></span>). In younger males and premenopausal females, patient selection must be individualized (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35378630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35378630'])">Ref</a></span>). Avoid use in females who are pregnant, who plan on becoming pregnant, or who are not using effective birth control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28585373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28585373'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Treatment and prevention:</b>
<b>Oral:</b> Immediate-release tablet: 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Duration of therapy:</b> The optimal duration of treatment has not been established; duration should be individualized based on continuation of glucocorticoid therapy and fracture risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28585373','lexi-content-ref-35378630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28585373','lexi-content-ref-35378630'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27086aba-8c10-446b-919b-fa327a4652c7">Paget disease of bone, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Paget disease of bone, treatment (alternative agent): Note:</b> For symptomatic patients with active disease and select patients with asymptomatic disease at risk of future complications; or prior to planned surgery at an active pagetic site (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25406796']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25406796'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Initial: <b>Oral:</b> Immediate-release tablet: 30 mg once daily for 2 months.</p>
<p style="text-indent:-2em;margin-left:4em;">Re-treatment: A second course (ie, 30 mg once daily for 2 months) may be considered following a posttreatment observation of ≥2 months if relapse occurs, or if treatment fails to normalize serum alkaline phosphatase. The Endocrine Society guidelines suggest retreatment may be required between 1 and 5 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25406796']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25406796'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bddc9a03-d14e-4739-9e13-19dee5b34eb0">Prostate cancer, bone loss associated with androgen deprivation therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, bone loss associated with androgen deprivation therapy (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use in males <b>without</b> bone metastases treated long term with androgen deprivation therapy who are at elevated risk of osteoporotic fractures (eg, T-score of −2.5 or lower, prior fragility fracture, or T-score between −1 and −2.5 at high fracture risk according to a risk assessment tool) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31990618','lexi-content-ref-31532726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31990618','lexi-content-ref-31532726'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 35 mg once weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23265571','lexi-content-ref-20456336']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23265571','lexi-content-ref-20456336'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Missed doses:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Once-weekly (immediate-release and delayed-release tablets):</i> If a once-weekly dose is missed, administer the next morning after remembered. Then return to the original scheduled day of the week on the once-weekly schedule (original scheduled day of the week); however, do not administer 2 doses on the same day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Monthly (150 mg once monthly immediate-release tablet): </i>If 150 mg once-monthly dose is missed, administer the next morning after remembered if the next month's scheduled dose is &gt;7 days away. If the next month's scheduled dose is within 7 days, wait until the next month's scheduled dose. For either scenario, then return to the original scheduled day of the month on the once-monthly schedule; however, do not administer &gt;150 mg within 7 days.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991596"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: <b>Oral:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 15 to 30 mL/minute: <b>Oral:</b> Use generally not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>). Based on limited data, use may be considered (in conjunction with patient’s nephrology team) for the treatment of osteoporosis in carefully selected patients with a history of fragility fracture and in whom the presence of CKD-MBD has been evaluated by a specialist and determined to be absent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16294264','lexi-content-ref-Miller.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16294264','lexi-content-ref-Miller.1'])">Ref</a></span>). If necessary, some experts recommend risedronate 35 mg <b>every other week</b> for not more than 3 years. Monitor serum creatinine at least annually and calcium, phosphorus, 25-hydroxyvitamin D, and parathyroid hormone concentrations regularly (eg, at least every 4 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Miller.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Miller.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;15 mL/minute: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not likely to be significantly dialyzed (large V<sub>d</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>): Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not likely to be significantly dialyzed (large V<sub>d</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>): Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988797"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). However, dosage adjustment unlikely because risedronate is not metabolized by the liver.</p></div>
<div class="block doe drugH1Div" id="F218587"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F55769424"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Atypical femur fractures</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Atypical <b>femur fractures </b>(AFFs) have been reported with bisphosphonate use. The fractures include subtrochanteric femur (bone just below the hip joint) and diaphyseal femur (long segment of the thigh bone). The benefits of therapy (when used for osteoporosis) generally outweigh the absolute risk of AFF within the first 5 years of treatment, especially in patients with high fracture risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26350171','lexi-content-ref-30907953']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26350171','lexi-content-ref-30907953'])">Ref</a></span>). The risk decreases after bisphosphonate discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32813950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32813950'])">Ref</a></span>). AFF is estimated to occur in ~0.2 % of bisphosphonate users after ≥5 years of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21343577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21343577'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Time-related. Long-term suppression of bone turnover may be primarily responsible; however, microdamage accumulation and alterations of collagen cross-linking have also been postulated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31497503','lexi-content-ref-23712442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31497503','lexi-content-ref-23712442'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; most fractures have occurred in patients receiving bisphosphonates for at least 3 to 5 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30169557','lexi-content-ref-31893493','lexi-content-ref-21343577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30169557','lexi-content-ref-31893493','lexi-content-ref-21343577'])">Ref</a></span>). Patients may experience prodromal pain weeks or months before the fracture occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20842676']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20842676'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Long-term treatment (&gt;3 to 5 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26350171','lexi-content-ref-32813950','lexi-content-ref-FDA.1','lexi-content-ref-25182228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26350171','lexi-content-ref-32813950','lexi-content-ref-FDA.1','lexi-content-ref-25182228'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Asian race (in North America) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30169557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30169557'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Femoral bowing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30169557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30169557'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Glucocorticoid use (&gt;1 year) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30169557','lexi-content-ref-32813950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30169557','lexi-content-ref-32813950'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI mucosal irritation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Esophagitis</b>, dysphagia, <b>esophageal ulcer</b>, erosive esophagitis, esophageal stenosis (rare) and esophageal perforation (rare) have been reported either with risedronate or with other oral bisphosphonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21736407','lexi-content-ref-22778283','lexi-content-ref-21343270']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21736407','lexi-content-ref-22778283','lexi-content-ref-21343270'])">Ref</a></span>). Oropharyngeal ulcer has also been noted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30461047','lexi-content-ref-20674418','lexi-content-ref-21816532']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30461047','lexi-content-ref-20674418','lexi-content-ref-21816532'])">Ref</a></span>). Experiencing a GI event increases the likelihood of decreased compliance at 1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27112533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27112533'])">Ref</a></span>) or discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16678644','lexi-content-ref-12947959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16678644','lexi-content-ref-12947959'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: GI mucosal irritation is secondary to the local effect of risedronate on the gastric mucosa (as opposed to a systemic effect) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; dependent upon the type of mucosal injury but case reports with alendronate have noted onset within 2 days to 12 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21736407','lexi-content-ref-21816532','lexi-content-ref-22778283','lexi-content-ref-21343270']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21736407','lexi-content-ref-21816532','lexi-content-ref-22778283','lexi-content-ref-21343270'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Incorrect administration technique (ie, &lt;180 mL water, lying down after administration) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent nonsteroidal anti-inflammatory drug or antithrombotic use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254','lexi-content-ref-30626809']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254','lexi-content-ref-30626809'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior GI issues (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25866298']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25866298'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypocalcemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">While transient decreases in serum calcium are expected with the use of risedronate (and all bisphosphonates) due to their mechanism of action, cases of symptomatic <b>hypocalcemia</b> have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16468539','lexi-content-ref-16769264']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16468539','lexi-content-ref-16769264'])">Ref</a></span>). This has been seen in Paget disease and post-thyroidectomy settings and is reversible with discontinuation of risedronate, regardless of cause.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: By decreasing osteoclast activity, calcium is not released into the bloodstream, causing a transient decrease in blood calcium. In patients with normally functioning parathyroid glands, calcium homeostasis is regained shortly after starting the bisphosphonate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8298198']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8298198'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; case reports have noted occurrence of symptomatic hypocalcemia within 10 days of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16468539','lexi-content-ref-16769264']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16468539','lexi-content-ref-16769264'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Baseline hypocalcemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Impaired kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254','lexi-content-ref-19570737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254','lexi-content-ref-19570737'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Impaired parathyroid function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254','lexi-content-ref-19570737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254','lexi-content-ref-19570737'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• IV bisphosphonate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Vitamin D deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254','lexi-content-ref-19570737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254','lexi-content-ref-19570737'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Thyroidectomy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19570737','lexi-content-ref-16468539']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19570737','lexi-content-ref-16468539'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Osteonecrosis of the jaw</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteonecrosis of the jaw</b> (ONJ) was first described in dental literature (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12966493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12966493'])">Ref</a></span>) with the use of IV bisphosphonates. However, there is conflicting evidence of whether this risk is seen with oral bisphosphonates, such as risedronate, or is simply an increased risk in those who are treated with agents for osteoporosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24758181','lexi-content-ref-24515577','lexi-content-ref-21764202']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24758181','lexi-content-ref-24515577','lexi-content-ref-21764202'])">Ref</a></span>). ONJ is most commonly reversible and not life-threatening; however, the possibility of ONJ increases the risk of nonadherence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28602783']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28602783'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; exact mechanism is unknown but several hypothesized mechanisms exist, such as oversuppression of bone turnover (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16243172']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16243172'])">Ref</a></span>), mucosal toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16454811']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16454811'])">Ref</a></span>), cytokine-mediated inflammation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17614762']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17614762'])">Ref</a></span>), and infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19371816','lexi-content-ref-25710950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19371816','lexi-content-ref-25710950'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; can be spontaneous or after insult, such as tooth extraction and/or dental implant procedures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254','lexi-content-ref-30393090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254','lexi-content-ref-30393090'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Alcohol use disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Anemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30393090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30393090'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cancer and anticancer therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Corticosteroid therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Dental extraction, dental implant procedures, and other oral surgical procedures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640','lexi-content-ref-30393090','lexi-content-ref-31329513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640','lexi-content-ref-30393090','lexi-content-ref-31329513'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30393090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30393090'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Extended duration (&gt;3 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640','lexi-content-ref-19570737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640','lexi-content-ref-19570737'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High-dose, IV bisphosphonate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Immunological disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30393090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30393090'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Oral surgery or trauma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Poor oral hygiene (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Poorly fitting dental appliance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Radiotherapy to head and neck (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30393090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30393090'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Tobacco smoking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F218548"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidences may vary with product, dose, and indication.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (8% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (2% to 12%), diarrhea (5% to 20%), nausea (4% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (31%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (3% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (7% to 33%), back pain (6% to 28%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia (2%), chest pain (7%), peripheral edema (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypocalcemia (≤5%), increased parathyroid hormone (8% to 9%; &gt;1.5 x ULN: ≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (3% to 7%), duodenitis (≤1%), dyspepsia (4% to 8%), gastritis (1% to 3%), gastroesophageal reflux disease (1% to 2%), glossitis (≤1%), upper abdominal pain (2% to 3%), vomiting (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Benign prostatic hyperplasia (5%), nephrolithiasis (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Acute phase reaction-like symptoms (≤8%; includes fever, influenza-like illness)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (6% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (7%), dizziness (3% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthropathy (7%), limb pain (2% to 4%), muscle spasm (1% to 2%), musculoskeletal pain (2%), myalgia (1% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Cataract (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (4%), flu-like symptoms (10%), pharyngitis (6%), rhinitis (6%), upper respiratory tract infection (3% to 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Iritis, uveitis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Endocrine &amp; metabolic: Hypophosphatemia (&lt;3% decrease from baseline)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous skin disease, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Esophageal ulcer, esophagitis, gastric ulcer</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Femur fracture (low-energy fractures, including atypical subtrochanteric and diaphyseal) (Park-Wyllie 2011), ostealgia, osteonecrosis of the jaw (rare: &lt;1%) (Lewiecki 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Exacerbation of asthma</p></div>
<div class="block coi drugH1Div" id="F218562"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to risedronate or any component of the formulation; hypocalcemia; inability to stand or sit upright for at least 30 minutes; abnormalities of the esophagus (eg, stricture, achalasia) which delay esophageal emptying</p></div>
<div class="block war drugH1Div" id="F218545"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone/joint/muscle pain: Infrequently, severe (and occasionally debilitating) bone, joint, and/or muscle pain have been reported during bisphosphonate treatment. The onset of pain ranged from a single day to several months. Consider discontinuing therapy in patients who experience severe symptoms; symptoms usually resolve upon discontinuation. Some patients experienced recurrence when rechallenged with the same drug or another bisphosphonate; avoid use in patients with a history of these symptoms in association with bisphosphonate therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery: Altered absorption and ulceration risk: Avoid oral bisphosphates after bariatric surgery; inadequate oral absorption and potential anastomotic ulceration may occur. If therapy is indicated, IV administered bisphosphonates are recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Glucocorticoid-induced osteoporosis: Evaluate sex steroid hormonal status prior to treatment initiation; consider appropriate hormone replacement if necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment (generally not recommended in patients with a CrCl &lt;30 mL/minute).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Not approved for use in pediatric patients with osteogenesis imperfecta due to lack of efficacy in reducing the risk of fracture.</p></div>
<div class="block foc drugH1Div" id="F218556"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Actonel: 35 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Actonel: 150 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 30 mg, 35 mg, 150 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Atelvia: 35 mg [contains edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 35 mg</p></div>
<div class="block geq drugH1Div" id="F218541"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F218564"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Atelvia Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">35 mg (per each): $79.97</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Risedronate Sodium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">35 mg (per each): $52.31 - $61.95</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Actonel Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">35 mg (per each): $102.30</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $443.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Risedronate Sodium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $8.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $61.95</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">35 mg (per each): $61.95</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $233.39 - $318.58</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868163"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Actonel: 35 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Actonel: 150 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 30 mg, 35 mg, 150 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Actonel DR: 35 mg [contains edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 35 mg</p></div>
<div class="block adm drugH1Div" id="F218559"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral: Note:</b> Avoid administration of oral calcium supplements, antacids, magnesium supplements/laxatives, and iron preparations for ≥30 minutes after risedronate administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Immediate-release tablet: Administer on an empty stomach with a full glass (6 to 8 oz) of <b>plain water</b> (not mineral water) ≥30 minutes before any food, drink, or other medications orally to avoid interference with absorption. Patient must remain sitting upright or standing for ≥30 minutes after taking (to reduce esophageal irritation). Tablet should be swallowed whole; do not crush or chew.</p>
<p style="text-indent:-2em;margin-left:2em;">Delayed-release tablet: Administer with ≥4 oz of <b>plain water</b> (not mineral water) immediately after breakfast. Patient must remain sitting upright or standing for ≥30 minutes after taking (to reduce esophageal irritation). Tablet should be swallowed whole; do not cut, split, crush, or chew.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Immediate-release formulation is available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, bisphosphonate therapy is known to cause local irritation to gastric mucosa, and strong consideration should be given to converting to IV bisphosphonate (ibandronate, zoledronic acid).</p></div>
<div class="block meg drugH1Div" id="F11441520"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Actonel: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F020835s052lbl.pdf&amp;token=YljK4Snzf8fk8zLIl0f9pc%2FhggB4UAeaUP3t5Pe3aQ8woxCoTlVu0yhAlTNp5xFz4dFBVgcG%2FavLLzqU0wGrXA%2BdGfPkzaWdW%2BFY9bLxrxM%3D&amp;TOPIC_ID=10242" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020835s052lbl.pdf</a></p>
<p style="text-indent:-2em;margin-left:4em;">Atelvia: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F022560s011lbl.pdf%23page%3D24&amp;token=NLj31wlfGQ1T%2FntebRF49z%2Bvdi3VOvLFAg6T6hhtocyMoRL5O6BJt2X%2F16t4ChN9aOPKrmysAWSm%2Fw%2BOljQ32mVA%2FS39BIQ3zRoU9fIQoVulNDToTEG9Yt0Yl4Aw5BeR&amp;TOPIC_ID=10242" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022560s011lbl.pdf#page=24</a></p></div>
<div class="block use drugH1Div" id="F218558"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoporosis, fracture risk reduction: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Actonel</i>: Treatment and prevention of osteoporosis in postmenopausal females; treatment of osteoporosis in males; treatment and prevention of glucocorticoid-induced osteoporosis (daily dosage of ≥7.5 mg prednisone or equivalent).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Atelvia, Actonel DR [Canadian product]</i>: Treatment of osteoporosis in postmenopausal females.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Paget disease:</b>
<i>Actonel</i>: Treatment of Paget disease of the bone.</p></div>
<div class="block off-label drugH1Div" id="F51256703"><span class="drugH1">Use: Off-Label: Adult</span><p>Prostate cancer, bone loss associated with androgen deprivation therapy</p></div>
<div class="block mst drugH1Div" id="F6049623"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Actonel may be confused with Actos</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Risedronate may be confused with alendronate</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300007"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F218550"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: May enhance the hypocalcemic effect of Bisphosphonate Derivatives. Aminoglycosides may enhance the nephrotoxic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiogenesis Inhibitors (Systemic): May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Bisphosphonate Derivatives may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Histamine H2 Receptor Antagonists: May increase the serum concentration of Risedronate. This applies specifically to delayed-release risedronate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May diminish the therapeutic effect of Risedronate. Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate. Management: Coadministration of PPIs or PCABs with delayed-release risedronate formulations is not recommended. Limit PPI/PCAB dose and duration during coadministration with risedronate as possible. Patients over age 70 are at higher risk of adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyvalent Cation Containing Products: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F218578"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;text-align:justify;display:inline">Food reduces absorption (similar to other bisphosphonates); mean oral bioavailability is decreased when given with food. Management: Administer immediate release tablet with at least 6 oz of plain water (not mineral water) ≥30 minutes before the first food or drink of the day other than water. Administer delayed release tablet with at least 4 ounces of plain water immediately after breakfast.</p></div>
<div class="block rep_considerations drugH1Div" id="F49322012"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Underlying causes of osteoporosis should be evaluated and treated prior to considering bisphosphonate therapy in premenopausal women; effective contraception is recommended when bisphosphonate therapy is required (Pepe 2020). Bisphosphonates are incorporated into the bone matrix and gradually released over time. Because exposure prior to pregnancy may theoretically increase the risk of fetal harm, most sources recommend discontinuing bisphosphonate therapy in females of reproductive potential as early as possible prior to a planned pregnancy. Use in premenopausal females should be reserved for special circumstances when rapid bone loss is occurring; a bisphosphonate with the shortest half-life should then be used (Bhalla 2010; Pereira 2012; Stathopoulos 2011). When bisphosphonate therapy is needed in a premenopausal woman, risedronate may be preferred based on its shorter half-life compared to other agents. Treatment should be discontinued 6 to 12 months prior to a planned conception (Machairiotis 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Oral bisphosphonates can be considered for the prevention of glucocorticoid-induced osteoporosis in premenopausal females with moderate to high risk of fracture who do not plan to become pregnant during the treatment period and who are using effective birth control (or are not sexually active); intravenous therapy should be reserved for high risk patients only (Buckley [ACR 2017]).</p></div>
<div class="block pri drugH1Div" id="F218565"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">It is not known if bisphosphonates cross the placenta, but fetal exposure is expected (Djokanovic 2008; Stathopoulos 2011).</p>
<p style="text-indent:0em;margin-top:2em;">Information related to the use of risedronate in pregnancy is available from small retrospective studies (Levy 2009; Sokal 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Bisphosphonates are incorporated into the bone matrix and gradually released over time. The amount available in the systemic circulation varies by drug, dose, and duration of therapy. Theoretically, there may be a risk of fetal harm when pregnancy follows the completion of therapy (hypocalcemia, low birth weight, and decreased gestation have been observed in some case reports); however, available data have not shown that exposure to bisphosphonates during pregnancy significantly increases the risk of adverse fetal events (Djokanovic 2008; Green 2014; Levy 2009; Machairiotis 2019; Sokal 2019; Stathopoulos 2011). Exposed infants should be monitored for hypocalcemia after birth (Djokanovic 2008; Stathopoulos 2011).</p></div>
<div class="block brc drugH1Div" id="F218566"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if risedronate is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F218567"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Ensure adequate calcium and vitamin D intake; if dietary intake is inadequate, dietary supplementation is recommended. Patients should consume:</p>
<p style="text-indent:-2em;margin-left:2em;">Calcium: 1,000 mg/day (males: 50 to 70 years of age) <b>or</b> 1,200 mg/day (females ≥51 years of age and males ≥71 years of age) (IOM 2011; NOF [Cosman 2014]).</p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D: 800 to 1,000 units daily (age ≥50 years) (NOF [Cosman 2014]). Recommended Dietary Allowance (RDA): 600 units daily (age ≤70 years) <b>or</b> 800 units daily (age ≥71 years) (IOM 2011).</p></div>
<div class="block mop drugH1Div" id="F218554"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Osteoporosis: Serial bone mineral density (BMD) should be evaluated at baseline and every 1 to 3 years on treatment (usually at ~2 years following initiation of therapy, then more or less frequently depending on patient-specific factors and stability of BMD) (AACE/ACE [Camacho 2020]; ES [Eastell 2019]; NOF [Cosman 2014]); evaluate BMD every 2 to 4 years during a drug holiday (ES [Eastell 2019]); in patients with combined risedronate and glucocorticoid treatment, evaluate BMD at initiation of glucocorticoid therapy and after 6 to 12 months, then every 2 to 3 years if patient continues to have significant osteoporosis risk factors (ACR [Buckley 2017]); annual measurements of height and weight, assessment of chronic back pain; serum calcium (prior to and during therapy) and 25(OH)D; consider measuring biochemical markers of bone turnover (eg, fasting serum CTX or urinary NTX) at baseline, 3 months, and 6 months, to assess treatment response, adherence to therapy, and/or possible malabsorption (ES [Eastell 2019]).</p>
<p style="text-indent:-2em;margin-left:2em;">Paget disease: Serum total alkaline phosphatase at 6 to 12 weeks for initial response to treatment (when bone turnover will have shown a substantial decline) and potentially at 6 months (maximal suppression of high bone turnover); following treatment completion, monitor at ~6- to 12-month intervals (ES [Singer 2014]); monitoring more specific biochemical markers of bone turnover (eg, serum P1NP, NTX, serum beta-CTx) is generally only warranted in patients with Paget disease who have abnormal liver or biliary tract function or when early assessment of response to treatment is needed (eg, spinal compression, very active disease) (ES [Singer 2014]); serum calcium (prior to and during therapy) and 25(OH)D; pain (posttreatment pain may not strictly correlate with increased biochemical markers [Ralston 2019]).</p>
<p style="text-indent:-2em;margin-left:2em;">Femur fracture in patients presenting with thigh or groin pain (during or after treatment; if fracture identified, also evaluate contralateral limb).</p></div>
<div class="block pha drugH1Div" id="F218544"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">A bisphosphonate which inhibits bone resorption via actions on osteoclasts or on osteoclast precursors; decreases the rate of bone resorption, leading to an indirect increase in bone mineral density. In Paget's disease, characterized by disordered resorption and formation of bone, inhibition of resorption leads to an indirect decrease in bone formation; but the newly-formed bone has a more normal architecture.</p></div>
<div class="block phk drugH1Div" id="F218561"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: May require weeks </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Rapid </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 13.8 L/kg </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~24% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: None </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Poor, ~0.54% to 0.75% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Initial: 1.5 hours; Terminal: 480 to 561 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: 1 to 3 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (up to 85%); feces (as unabsorbed drug)</p></div>
<div class="block phksp drugH1Div" id="F51159788"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance decreased ~70% with CrCl 30 mL/minute.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F218568"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Ductonar | Rentop | Ribastamin | Ridron | Risedon</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Risedronat arcana | Risedronat ratiopharm | Risedronat stada</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Acris | Actonel | Actonel once a month | Actonel Once-a-Week | Apo risedronate | Atelvia | Risedro once a week | Risedronate an | Risedronate ga | Risedronate sandoz</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Risedon | Risonet | Salost | Sedron</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Risedreenos | Risedronaat Sandoz | Risedronate Apotex | Risedronate eg | Risedronate Mylan | Risedronate Ranbaxy | Risedronate Teva</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Actonel Once-a-Week | Risendros | Rizida | Zilar</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Actonel chronos | D'orto | Fixenato | Indosso | Osteoblock | Osteotrat | Risedronato sodico | Risedronel | Risedross | Risonato</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Risedronat helvepharm | Risedronat Mepha</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Actonel</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ji wei | Wei shan</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Osteoclax | Residron | Risedrinato sodico | Risedronato MK</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Melenor | Risedronat | Risedronat Mylan | Risedronat teva | Risendros | Rismyl | Tevanel</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Acara | Actonel | Actonel einmal woechentlich | Risedron hexal | Risedronat al | Risedronat Aurobindo | Risedronat Bluefish | Risedronat heumann | Risedronat Sandoz | Risedronat stada | Risedronat teva | Risedronsaeure | Risedronsaeure 1a pharma | Risedronsaeure abz | Risedronsaeure actavis | Risedronsaeure ct | Risedronsaeure ratiopharm</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Risedronatnatrium "Actavis"</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Esat | Maxidronato | Rised</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Actonel</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Actonel o.a.w. | Melenor | Norifaz | Ribidron | Risedronate sodium accord | Risedronate sodium Actavis | Risendros | Risonate</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Actoweek | Risaldene | Risefutal | Riseonate</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Atalin | Miosen Semanal | Risedronato ababor | Risedronato accord healthcare | Risedronato alter | Risedronato Apotex | Risedronato arisonel | Risedronato cinfa | Risedronato kern pharma | Risedronato ratiopharm | Risedronato Semanal | Risedronato Semanal Actavis | Risedronato semanal bluefish | Risedronato Semanal Hexal | Risedronato Tecnigen | Risedronato Teva | Risemyl Semanal</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Optinate | Risedronat Actavis | Risedronat Orifarm | Risedronat Sandoz | Risedronat stada | Risedronat teva | Risedronate Bluefish | Riseos | Riseratio | Vionate</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Risedronate actavis | Risedronate Almus | Risedronate Alter | Risedronate arrow | Risedronate arrow generiques | Risedronate bgr | Risedronate biogaran | Risedronate Bluefish | Risedronate cristers | Risedronate eg | Risedronate Evolugen | Risedronate isomed | Risedronate Mylan | Risedronate Phr lab | Risedronate qualimed | Risedronate Ranbaxy | Risedronate ratiopharm | Risedronate sandoz | Risedronate Teva | Risedronate winthrop | Risedronate zentiva | Risedronate zydus</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Actonel</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Axedronate | Bondamax | Bondapen | Bonmate | Mededronate | Medosteo | Motivus | Ostoris | Risedronate sandoz | Risedronate Teva | Risedronate/generics | Riselib | Risendron | Risosfon</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Actojenic | Actonel | Pms risedronate | Risedronate sandoz</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Bonna | Risbon</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Boneact | Juverital | Norifaz | Optirize | Risedronat galex | Risendros</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Osteonate | Retonel | Ristonat</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Ridate once a week | Risedronate | Risedronate gerard | Risedronate pinewood once a week | Risonate | Risontel once a week</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Ribone</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Fossical | Gemfos | Risofos</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Acridon | Actonel | Avestra | Bencomin | Cedravis | Fodren | Medeoros | Optinate | Rilovans | Riseceus | Risectol | Risedronato | Risedronato accordpharma | Risedronato actavis | Risedronato aurobindo | Risedronato Bluefish | Risedronato cipla | Risedronato Doc | Risedronato Doc Generici | Risedronato EG | Risedronato Germed | Risedronato Mylan | Risedronato pensa | Risedronato Ranbaxy | Risedronato Sandoz | Risedronato Tecnigen | Risedronato Teva | Risedronato zentiva | Risencal | Simedral | Trimmer | Vesnar</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Actonel one a week</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Benet | Risedronate na | Risedronate na ffp | Sodium risedronate | Sodium risedronate towa</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Gemfos | R fos | Risofos</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Actbone | Actobon | Actobone | Actogenic | Actojenic | Actonate | Actonel | Actonel ec | Actoqueen | Actoril | Actoron | Actosin | Alto riton | Altoriton | Aprogen risedronate sodium | Bi tonel | Bonegrow | Bonel | Bonemate | Bonesave | Bonnel | Bonseron | Bontil | Bontonel | Bontrol | Ckd risedronate sodium monhydrate | Dronel | Fosnel | Gynotinel | Hudron | Huniz risedronate sodium | Kantonel | Myungin risedronate sodium | Niseron | Optinate | Osnel | Osonel | Osteone | Osteron | Ostol | Ostonel | Ostron | Posnil | Ribon | Ricalbon | Richbon | Richbon month | Richbone | Richbonemonth | Ridbon | Ridmax | Ridonel | Ridron | Ridroqueen | Rigolda | Rimebon | Rinate | Rinesate | Riront | Risebone | Risede | Risedrin | Risedro | Risedron | Risedronate | Risedronate hutecs | Risellon | Risemac | Risen | Risena | Risenate | Risend | Risenel | Risenex | Risenil | Riserin | Risero | Riseron | Riserone | Riset | Riseto | Risetron | Risez | Risidro | Risnel | Ristonel | Riton | Ritonel | Rizonel | Rp risenate | Sedonel | Sedron | Titonel | Wintonel | Withus risedronate | Yungtonel | Zanical</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Apo risedronate | Dronel | Madronate | Osteral | Pms risedronate | Risedronate | Risofos R</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Actonel o.a.w. | Melenor | Norifaz | Ribidron | Risedronate sodium Actavis | Risedronate sodium portfarma | Risendros | Risonate</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Risedreenos | Risedronate eg | Risedronsaeure</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Melenor | Norifaz | Ribidron | Risedronate actavis | Risedronate sodium portfarma | Risendros | Risonate</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Noporose | Risate</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Alesone | Enospag | Farmafosfodron | Misodron | Natolox | Reosvec | Risedronato | Tecnodron</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Actonel</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Actonel wekelijks | Natriumrisedronaat | Natriumrisedronaat sandoz wekelijks | Risedronaatnatrium | Risedronaatnatrium Actavis | Risedronaatnatrium Bluefish | Risedronaatnatrium cf | Risedronaatnatrium mylan wekelijks | Risedronaatnatrium wekelijks | Risedronaatnatrium wekelijks pch</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Optinate | Optinate septimum | Risedronat amneal | Risedronat Orifarm</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Risedronate sandoz</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Risate | Risendal</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Residron</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Atconate | Azebone | B nate | Bisfos | Bonema | Dronate | Freal | Osteorise | Redrona | Risefos | Risonate | Udro</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Norifaz | Resorpate</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Atelvia</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Norifaz | Risedronato | Risedronato de sodio | Risedronato de sodio actavis | Risedronato de sodio alter | Risedronato de sodio bluepharma | Risedronato de sodio ciclum | Risedronato de sodio farmoz | Risedronato de sodio generis | Risedronato de sodio germed | Risedronato de sodio GP | Risedronato de sodio Labesfal | Risedronato de sodio mepha | Risedronato de sodio Mylan | Risedronato de sodio ratiopharm | Risedronato de sodio Teva | Risedronato de sodio Vitalion | Zectoel</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Ductonar</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Juverital | Lorine | Osodens | Osteoron | Risedronat Aurobindo | Risedronat teva</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Risarteva | Risendros</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Fortipan | Norsed | Optinate | Optinate septimum | Risedronat 2care4 | Risedronat abacus medicine | Risedronat Actavis | Risedronat amneal | Risedronat ebb | Risedronat jubilant | Risedronat Orifarm | Risedronat paranova | Risedronat Sandoz | Risedronat teva | Risedronate Bluefish | Risedronate Ranbaxy | Risedronate Stada</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Actonel</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Risedronat galex</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Bifodron | Melenor | Norifaz | Risedronat galex | Risedronat Mylan | Risedronat ratiopharm | Risedronat teva | Risendros</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Palibone</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Aktonate | Ostenel | Risonel</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Acsonat | Actonel | Arilex | Goyart</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Walkin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Ribis | Risostin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Gemfos</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Dronacal | Orafix</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Actonel | Oxidren | Risedronato</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Actamax | Actonel</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Actonel.1">
<a name="Actonel.1"></a>Actonel (risedronate) [prescribing information]. Irvine, CA: Allergan; November 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Actonel.2">
<a name="Actonel.2"></a>Actonel and Actonel DR (risedronate) [product monograph]. St-Laurent, Ontario, Canada: AbbVie Corporatoin; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26350171">
<a name="26350171"></a>Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research [published correction appears in <i>J Bone Miner Res</i>. 2016;31(10):1910]. <i>J Bone Miner Res</i>. 2016;31(1):16-35. doi: 10.1002/jbmr.2708.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/26350171/pubmed" id="26350171" target="_blank">26350171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21736407">
<a name="21736407"></a>Aibar Arregui MA, de Escalante Yangüela B, Muñoz Villalengua M, Garcés Horna V. Esophageal stenosis caused by alendronate. <i>Rev Esp Enferm Dig</i>. 2011;103(6):338-339. doi:10.4321/s1130-01082011000600015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/21736407/pubmed" id="21736407" target="_blank">21736407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28169118">
<a name="28169118"></a>Alibhai SMH, Zukotynski K, Walker-Dilks C, et al; Cancer Care Ontario Genitourinary Cancer Disease Site Group. Bone health and bone-targeted therapies for prostate cancer: a programme in evidence-based care - Cancer Care Ontario clinical practice guideline. <i>Clin Oncol (R Coll Radiol)</i>. 2017;29(6):348-355. doi:10.1016/j.clon.2017.01.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/28169118/pubmed" id="28169118" target="_blank">28169118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19371816">
<a name="19371816"></a>Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. <i>J Oral Maxillofac Surg</i>. 2009;67(5 Suppl):61-70. doi:10.1016/j.joms.2009.01.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/19371816/pubmed" id="19371816" target="_blank">19371816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16873332">
<a name="16873332"></a>American Dental Association Council on Scientific Affairs, “Dental Management of Patients Receiving Oral Bisphosphonate Therapy,” <i>JADA</i>, 2006, 137(8):1144-50. Available at http://jada.ada.org/article/S0002-8177(14)64960-6/pdf
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/16873332/pubmed" id="16873332" target="_blank">16873332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Atelvia.1">
<a name="Atelvia.1"></a>Atelvia (risedronate) [prescribing information]. Rockaway, NJ: Warner Chilcott (US) LLC; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20534366">
<a name="20534366"></a>Bhalla AK, "Management of Osteoporosis in a Pre-menopausal Woman," <i>Best Pract Res Clin Rheumatol</i>, 2010, 24(3):313-27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/20534366/pubmed" id="20534366" target="_blank">20534366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30169557">
<a name="30169557"></a>Black DM, Abrahamsen B, Bouxsein ML, Einhorn T, Napoli N. Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. <i>Endocr Rev</i>. 2019;40(2):333-368. doi:10.1210/er.2018-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/30169557/pubmed" id="30169557" target="_blank">30169557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32813950">
<a name="32813950"></a>Black DM, Geiger EJ, Eastell R, et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. <i>N Engl J Med</i>. 2020;383(8):743-753. doi:10.1056/NEJMoa1916525<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/32813950/pubmed" id="32813950" target="_blank">32813950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28585373">
<a name="28585373"></a>Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. <i>Arthritis Rheumatol</i>. 2017;69(8):1521-1537. doi:10.1002/art.40137<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/28585373/pubmed" id="28585373" target="_blank">28585373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32427503">
<a name="32427503"></a>Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. <i>Endocr Pract</i>. 2020;26(suppl 1):s1-s46. doi:10.4158/GL-2020-0524SUPPL<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/32427503/pubmed" id="32427503" target="_blank">32427503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8298198">
<a name="8298198"></a>Chesnut CH 3rd, Harris ST. Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women. <i>Osteoporos Int</i>. 1993;3 Suppl 3:S17-S19. doi:10.1007/BF01623003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/8298198/pubmed" id="8298198" target="_blank">8298198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24758181">
<a name="24758181"></a>Chiu WY, Chien JY, Yang WS, Juang JM, Lee JJ, Tsai KS. The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene. <i>J Clin Endocrinol Metab</i>. 2014;99(8):2729-2735. doi:10.1210/jc.2013-4119<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/24758181/pubmed" id="24758181" target="_blank">24758181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23265571">
<a name="23265571"></a>Choo R, Lukka H, Cheung P, et al. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy. <i>Int J Radiat Oncol Biol Phys</i>. 2013;85(5):1239-1245.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/23265571/pubmed" id="23265571" target="_blank">23265571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25182228">
<a name="25182228"></a>Cosman F, de Beur SJ, LeBoff MS, et al; National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis [published correction appears in <i>Osteoporos Int</i>. 2015;26(7):2045-2047]. <i>Osteoporos Int</i>. 2014;25(10):2359-2381. doi: 10.1007/s00198-014-2794-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/25182228/pubmed" id="25182228" target="_blank">25182228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19175968">
<a name="19175968"></a>Djokanovic N, Klieger-Grossmann C, and Koren G, "Does Treatment With Bisphosphonates Endanger the Human Pregnancy?" <i>J Obstet Gynaecol Can</i>, 2008, 30(12):1146-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/19175968/pubmed" id="19175968" target="_blank">19175968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30907953">
<a name="30907953"></a>Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1595-1622. doi:10.1210/jc.2019-00221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/30907953/pubmed" id="30907953" target="_blank">30907953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19047674">
<a name="19047674"></a>Edwards BJ, Hellstein JW, Jacobsen PL, et al, "Updated Recommendations for Managing the Care of Patients Receiving Oral Bisphosphonate Therapy: An Advisory Statement From the American Dental Association Council on Scientific Affairs," <i> J Am Dent Assoc</i>, 2008, 139(12):1674-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/19047674/pubmed" id="19047674" target="_blank">19047674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30461047">
<a name="30461047"></a>Eguchi T, Basugi A, Kanai I, Miyata Y, Hamada Y. Multiple oral ulcers caused by incorrect use of oral bisphosphonate in a patient with dementia: A case report. <i>Gerodontology</i>. 2019;36(1):82-84. doi:10.1111/ger.12378<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/30461047/pubmed" id="30461047" target="_blank">30461047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>FDA drug safety communication: safety update for osteoporosis drugs, bisphosphonates, and atypical fractures. Food and Drug Administration. Updated October 13, 2010. Accessed May 14, 2021. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-update-osteoporosis-drugs-bisphosphonates-and-atypical" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-update-osteoporosis-drugs-bisphosphonates-and-atypical</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20508948">
<a name="20508948"></a>Filleul O, Crompot E, and Saussez S, "Bisphosphonate-Induced Osteonecrosis of the Jaw: A Review of 2,400 Patient Cases," <i>J Cancer Res Clin Oncol</i>, 2010, 136(8):1117-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/20508948/pubmed" id="20508948" target="_blank">20508948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Finkelstein.1">
<a name="Finkelstein.1"></a>Finkelstein JS, Yu Ew. Treatment of osteoporosis in men. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 14, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14594094">
<a name="14594094"></a>French AE, Kaplan N, Lishner M, et al, “Taking Bisphosphonates During Pregnancy,” <i>Can Fam Physician</i>, 2003, 49:1281-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/14594094/pubmed" id="14594094" target="_blank">14594094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17614762">
<a name="17614762"></a>Galluzzo S, Santini D, Vincenzi B, et al. Immunomodulating role of bisphosphonates on human gamma delta T cells: an intriguing and promising aspect of their antitumour activity. <i>Expert Opin Ther Targets</i>. 2007;11(7):941-954. doi:10.1517/14728222.11.7.941<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/17614762/pubmed" id="17614762" target="_blank">17614762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25404594">
<a name="25404594"></a>Green SB, Pappas AL. Effects of maternal bisphosphonate use on fetal and neonatal outcomes. <i>Am J Health Syst Pharm</i>. 2014;71(23):2029-2036.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/25404594/pubmed" id="25404594" target="_blank">25404594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35378630">
<a name="35378630"></a>Gregson CL, Armstrong DJ, Bowden J, et al. UK clinical guideline for the prevention and treatment of osteoporosis. <i>Arch Osteoporos.</i> 2022;17(1):58. doi:10.1007/s11657-022-01061-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/35378630/pubmed" id="35378630" target="_blank">35378630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28602783">
<a name="28602783"></a>Hall SF, Edmonds SW, Lou Y, et al. Patient-reported reasons for nonadherence to recommended osteoporosis pharmacotherapy. <i>J Am Pharm Assoc (2003)</i>. 2017;57(4):503-509. doi:10.1016/j.japh.2017.05.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/28602783/pubmed" id="28602783" target="_blank">28602783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16454811">
<a name="16454811"></a>Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. <i>J Oral Pathol Med</i>. 2006;35(3):155-160. doi:10.1111/j.1600-0714.2006.00391.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/16454811/pubmed" id="16454811" target="_blank">16454811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22041409">
<a name="22041409"></a>Hellstein JW, Adler RA, Edwards B, et al, "Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis: Executive Summary of Recommendations From the American Dental Association Council on Scientific Affairs," <i>J Am Dent Assoc</i>, 2011, 142(11):1243-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/22041409/pubmed" id="22041409" target="_blank">22041409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hellstein.1">
<a name="Hellstein.1"></a>Hellstein JW, Adler RA, Edwards B, et al, "Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis: Recommendations From the American Dental Association Council on Scientific Affairs," 2011, Available at http://www.ada.org/sections/professionalResources/pdfs/topics_ARONJ_report.pdf. Accessed February 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>IOM (Institute of Medicine), <i>Dietary Reference Intakes for Calcium and Vitamin D,</i> Washington, DC: The National Academies Press, 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25710950">
<a name="25710950"></a>Katsarelis H, Shah NP, Dhariwal DK, Pazianas M. Infection and medication-related osteonecrosis of the jaw. <i>J Dent Res</i>. 2015;94(4):534-539. doi:10.1177/0022034515572021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/25710950/pubmed" id="25710950" target="_blank">25710950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25414052">
<a name="25414052"></a>Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. <i>J Bone Miner Res.</i> 2015; 30(1):3-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/25414052/pubmed" id="25414052" target="_blank">25414052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20674418">
<a name="20674418"></a>Kharazmi M, Sjöqvist K, Rizk M, Warfvinge G. Oral ulcer associated with alendronate: a case report. <i>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</i>. 2010;110(6):e11-e13. doi:10.1016/j.tripleo.2010.04.035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/20674418/pubmed" id="20674418" target="_blank">20674418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21816532">
<a name="21816532"></a>Kharazmi M, Sjöqvist K, Warfvinge G. Oral ulcers, a little known adverse effect of alendronate: review of the literature. <i>J Oral Maxillofac Surg</i>. 2012;70(4):830-836. doi:10.1016/j.joms.2011.03.046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/21816532/pubmed" id="21816532" target="_blank">21816532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17663640">
<a name="17663640"></a>Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. <i>J Bone Miner Res</i>. 2007;22(10):1479-1491. doi:10.1359/jbmr.0707onj<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/17663640/pubmed" id="17663640" target="_blank">17663640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19059370">
<a name="19059370"></a>Levy S, Fayez I, Taguchi N, et al, "Pregnancy Outcome Following <i>in utero</i> Exposure to Bisphosphonates," <i>Bone</i>, 2009, 44(3):428-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/19059370/pubmed" id="19059370" target="_blank">19059370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lewiecki.1">
<a name="Lewiecki.1"></a>Lewiecki EM. Prevention of osteoporosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 14, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21504254">
<a name="21504254"></a>Lewiecki EM. Safety of long-term bisphosphonate therapy for the management of osteoporosis. <i>Drugs</i>. 2011;71(6):791-814. doi:10.2165/11585470-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/21504254/pubmed" id="21504254" target="_blank">21504254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24515577">
<a name="24515577"></a>Lin TC, Yang CY, Kao Yang YH, Lin SJ. Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population. <i>Osteoporos Int</i>. 2014;25(5):1503-1511. doi:10.1007/s00198-014-2624-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/24515577/pubmed" id="24515577" target="_blank">24515577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19772941">
<a name="19772941"></a>Lo JC, O'Ryan FS, Gordon NP, et al, “Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure,” <i>J Oral Maxillofac Surg</i>, 2010, 68(2):243-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/19772941/pubmed" id="19772941" target="_blank">19772941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31497503">
<a name="31497503"></a>Lockwood M, Banderudrappagari R, Suva LJ, Makhoul I. Atypical femoral fractures from bisphosphonate in cancer patients - Review. <i>J Bone Oncol</i>. 2019;18:100259. doi:10.1016/j.jbo.2019.100259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/31497503/pubmed" id="31497503" target="_blank">31497503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31539355">
<a name="31539355"></a>Machairiotis N, Ntali G, Kouroutou P, Michala L. Clinical evidence of the effect of bisphosphonates on pregnancy and the infant. <i>Horm Mol Biol Clin Investig</i>. 2019;40(2). doi:10.1515/hmbci-2019-0021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/31539355/pubmed" id="31539355" target="_blank">31539355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20061894">
<a name="20061894"></a>Management of Osteoporosis in Postmenopausal Women: 2010 Position Statement of The North American Menopause Society. <i>Menopause</i>. 2010;17(1):25-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/20061894/pubmed" id="20061894" target="_blank">20061894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31893493">
<a name="31893493"></a>Marchand D, Loshak H. <i>Duration of Bisphosphonate Treatment for Patients with Osteoporosis: A Review of Clinical Effectiveness and Guidelines</i>. Canadian Agency for Drugs and Technologies in Health; October 4, 2019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/31893493/pubmed" id="31893493" target="_blank">31893493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12966493">
<a name="12966493"></a>Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. <i>J Oral Maxillofac Surg</i>. 2003;61(9):1115-1117. doi:10.1016/s0278-2391(03)00720-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/12966493/pubmed" id="12966493" target="_blank">12966493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16243172">
<a name="16243172"></a>Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. <i>J Oral Maxillofac Surg</i>. 2005;63(11):1567-1575. doi:10.1016/j.joms.2005.07.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/16243172/pubmed" id="16243172" target="_blank">16243172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17307586">
<a name="17307586"></a>Mavrokokki T, Cheng A, Stein B, et al. Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia. <i>J Oral Maxillofac Surg</i>. 2007;65(3):415-423.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/17307586/pubmed" id="17307586" target="_blank">17307586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16294264">
<a name="16294264"></a>Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. <i>J Bone Miner Res</i>. 2005;20(12):2105-2115. doi:10.1359/JBMR.050817<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/16294264/pubmed" id="16294264" target="_blank">16294264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Miller.1">
<a name="Miller.1"></a>Miller PD. Osteoporosis in patients with chronic kidney disease: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 15, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27112533">
<a name="27112533"></a>Modi A, Sajjan S, Michael Lewiecki E, Harris ST, Papadopoulos Weaver J. Relationship between gastrointestinal events and compliance with osteoporosis therapy: an administrative claims analysis of the US managed care population. <i>Clin Ther</i>. 2016;38(5):1074-1080. doi:10.1016/j.clinthera.2016.03.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/27112533/pubmed" id="27112533" target="_blank">27112533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25866298">
<a name="25866298"></a>Modi A, Siris ES, Steve Fan CP, Sajjan S. Gastrointestinal events among patients initiating osteoporosis therapy: a retrospective administrative claims database analysis. <i>Clin Ther</i>. 2015;37(6):1228-1234. doi:10.1016/j.clinthera.2015.03.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/25866298/pubmed" id="25866298" target="_blank">25866298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22778283">
<a name="22778283"></a>Munigoti S, Frazer R, Rees A, Blackshaw G, Thomas G, Roberts A. A rare complication with a single dose of alendronate. <i>BMJ Case Rep</i>. 2010;2010:bcr0220102738. doi:10.1136/bcr.02.2010.2738<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/22778283/pubmed" id="22778283" target="_blank">22778283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30393090">
<a name="30393090"></a>Nicolatou-Galitis O, Schiødt M, Mendes RA, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. <i>Oral Surg Oral Med Oral Pathol Oral Radiol</i>. 2019;127(2):117-135. doi:10.1016/j.oooo.2018.09.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/30393090/pubmed" id="30393090" target="_blank">30393090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34448749">
<a name="34448749"></a>North American Menopause Society. Management of osteoporosis in postmenopausal women: the 2021 position statement of the North American Menopause Society. <i>Menopause</i>. 2021;28(9):973-997. doi:10.1097/GME.0000000000001831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/34448749/pubmed" id="34448749" target="_blank">34448749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19570737">
<a name="19570737"></a>Papapetrou PD. Bisphosphonate-associated adverse events. <i>Hormones (Athens)</i>. 2009;8(2):96-110. doi:10.14310/horm.2002.1226<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/19570737/pubmed" id="19570737" target="_blank">19570737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21343577">
<a name="21343577"></a>Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. <i>JAMA</i>. 2011;305(8):783-789. doi:10.1001/jama.2011.190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/21343577/pubmed" id="21343577" target="_blank">21343577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21343270">
<a name="21343270"></a>Paul AK, Seetharaman M. Esophageal stricture associated with alendronate use. <i>CMAJ</i>. 2011;183(7):E429. doi:10.1503/cmaj.100415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/21343270/pubmed" id="21343270" target="_blank">21343270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16678644">
<a name="16678644"></a>Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. <i>Clin Ther</i>. 2006;28(2):236-242. doi:10.1016/j.clinthera.2006.01.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/16678644/pubmed" id="16678644" target="_blank">16678644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32453819">
<a name="32453819"></a>Pepe J, Body JJ, Hadji P, et al. Osteoporosis in premenopausal women: a clinical narrative review by the ECTS and the IOF [published online May 26, 2020]. <i>J Clin Endocrinol Metab</i>. doi:10.1210/clinem/dgaa306<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/32453819/pubmed" id="32453819" target="_blank">32453819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22885424">
<a name="22885424"></a>Pereira RM, Carvalho JF, Paula AP, et al, "Guidelines for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis," <i>Rev Bras Reumatol</i>, 2012, 52(4):580-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/22885424/pubmed" id="22885424" target="_blank">22885424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30803025">
<a name="30803025"></a>Ralston SH, Corral-Gudino L, Cooper C, et al. Diagnosis and management of Paget's disease of bone in adults: a clinical guideline<i>. J Bone Miner Res</i>. 2019;34(4):579-604. doi: 10.1002/jbmr.3657.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/30803025/pubmed" id="30803025" target="_blank">30803025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16468539">
<a name="16468539"></a>Richmond BK. Profound refractory hypocalcemia after thyroidectomy in a patient receiving chronic oral bisphosphonate therapy. <i>Am Surg</i>. 2005;71(10):872-873.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/16468539/pubmed" id="16468539" target="_blank">16468539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosen.1">
<a name="Rosen.1"></a>Rosen HN, Drezner MK. Overview of the management of osteoporosis in postmenopausal women. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 4, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20871729">
<a name="20871729"></a>Ruggiero S, Gralow J, Marx RE, et al, "Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With Cancer," <i>J Clin Oncol</i>, 2006, 2(1):7-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/20871729/pubmed" id="20871729" target="_blank">20871729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31990618">
<a name="31990618"></a>Saylor PJ, Rumble RB, Tagawa S, et al. Bone health and bone-targeted therapies for prostate cancer: ASCO endorsement of a Cancer Care Ontario guideline. <i>J Clin Oncol</i>. 2020;38(15):1736-1743. doi:10.1200/JCO.19.03148<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/31990618/pubmed" id="31990618" target="_blank">31990618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23712442">
<a name="23712442"></a>Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. <i>J Bone Miner Res</i>. 2014;29(1):1-23. doi:10.1002/jbmr.1998<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/23712442/pubmed" id="23712442" target="_blank">23712442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20842676">
<a name="20842676"></a>Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research [published correction appears in <i>J Bone Miner Res</i>. 2011;26(8):1987]. <i>J Bone Miner Res</i>. 2010;25(11):2267-2294. doi:10.1002/jbmr.253<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/20842676/pubmed" id="20842676" target="_blank">20842676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31532726">
<a name="31532726"></a>Shapiro CL, Van Poznak C, Lacchetti C, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. <i>J Clin Oncol</i>. 2019;37(31):2916-2946. doi: 10.1200/JCO.19.01696.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/31532726/pubmed" id="31532726" target="_blank">31532726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25406796">
<a name="25406796"></a>Singer FR, Bone HG, Hosking DJ, et al. Paget's disease of bone: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2014;99(12):4408-4422.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/25406796/pubmed" id="25406796" target="_blank">25406796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24577348">
<a name="24577348"></a>Siris ES, Adler R, Bilezikian J, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. <i>Osteoporos Int</i>. 2014;25(5):1439-1443. doi: 10.1007/s00198-014-2655-z.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/24577348/pubmed" id="24577348" target="_blank">24577348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30171300">
<a name="30171300"></a>Sokal A, Elefant E, Leturcq T, Beghin D, Mariette X, Seror R. Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study. <i>Osteoporos Int</i>. 2019;30(1):221-229.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/30171300/pubmed" id="30171300" target="_blank">30171300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22281884">
<a name="22281884"></a>Stathopoulos IP, Liakou CG, Katsalira A, et al, "The Use of Bisphosphonates in Women Prior to or During Pregnancy and Lactation," <i>Hormones (Athens)</i>, 2011, 10(4):280-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/22281884/pubmed" id="22281884" target="_blank">22281884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20456336">
<a name="20456336"></a>Taxel P, Dowsett R, Richter L, Fall P, Klepinger A, Albertsen P. Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. <i>BJU Int</i>. 2010;106(10):1473-1476.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/20456336/pubmed" id="20456336" target="_blank">20456336</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12947959">
<a name="12947959"></a>Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. <i>Am J Med</i>. 2003;115(3):209-216. doi:10.1016/s0002-9343(03)00362-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/12947959/pubmed" id="12947959" target="_blank">12947959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21764202">
<a name="21764202"></a>Vestergaard P, Schwartz K, Rejnmark L, Mosekilde L, Pinholt EM. Oral bisphosphonate use increases the risk for inflammatory jaw disease: a cohort study. <i>J Oral Maxillofac Surg</i>. 2012;70(4):821-829. doi:10.1016/j.joms.2011.02.093<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/21764202/pubmed" id="21764202" target="_blank">21764202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22675062">
<a name="22675062"></a>Watts NB, Adler RA, Bilezikian JP, et al; Endocrine Society. Osteoporosis in men: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2012;97(6):1802-1822. doi: 10.1210/jc.2011-3045.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/22675062/pubmed" id="22675062" target="_blank">22675062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20173017">
<a name="20173017"></a>Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. <i>J Clin Endocrinol Metab</i>. 2010;95(4):1555-1565. doi: 10.1210/jc.2009-1947.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/20173017/pubmed" id="20173017" target="_blank">20173017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16769264">
<a name="16769264"></a>Whitson HE, Lobaugh B, Lyles KW. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone. <i>Bone</i>. 2006;39(4):954-958. doi:10.1016/j.bone.2006.04.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/16769264/pubmed" id="16769264" target="_blank">16769264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30626809">
<a name="30626809"></a>Yamamoto K, Kishino M, Nakamura S, Tokushige K. Symptoms and upper gastrointestinal mucosal injury associated with bisphosphonate therapy. <i>Intern Med</i>. 2019;58(8):1049-1056. doi:10.2169/internalmedicine.1271-18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/30626809/pubmed" id="30626809" target="_blank">30626809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31329513">
<a name="31329513"></a>Yarom N, Shapiro CL, Peterson DE, et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. <i>J Clin Oncol</i>. 2019;37(25):2270-2290. doi:10.1200/JCO.19.01186<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/31329513/pubmed" id="31329513" target="_blank">31329513</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10242 Version 338.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
